WATS stock forecast, quote, news & analysis

Key Takeaways

• Waters Corporation (WATS) shares declined roughly 12.9% over the last 30 days, falling from about $20.33 to $17.71.
• The pullback extends a longer slide: the stock is down approximately 7% over the past quarter and well below its early-July levels near $26.
• A sizable GAAP net loss tied to the integration of Becton Dickinson's (BDX) biosciences and diagnostics business has weighed on investor sentiment.
• Insider selling and a senior leadership transition have added to near-term uncertainty around the shares.
• Mixed analyst actions, including several Hold ratings, have kept the stock range-bound even as some firms raised price targets.
• Positive catalysts such as new diagnostics partnerships and an AI-enabled LC-MS launch have not yet reversed the downtrend.
• For more details, investors can review the company's Price Targets, Earnings, and Forecast pages.
• Traders can also explore Trending AI Robots for additional data-driven market insights.

Waters Corporation (WATS) Company Overview and Market Position

Waters Corporation designs, manufactures, sells, and services analytical instruments and software used across pharmaceutical, life science, industrial, food, and environmental testing markets. Its core portfolio includes liquid chromatography (LC), mass spectrometry (MS), and thermal analysis (TA) systems, supported by a recurring revenue base of columns, consumables, and service plans. Following its combination with Becton Dickinson's Biosciences and Diagnostic Solutions unit, Waters has expanded into diagnostics and in-vitro testing, significantly broadening its addressable market. The company competes with peers such as Agilent Technologies (A) and Thermo Fisher Scientific (TMO), and investors track the stock for its exposure to life-science instrument spending and its growing diagnostics footprint.

Waters Corporation (WATS) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, WATS declined approximately 12.9%, moving from a closing level near $20.33 in late September to roughly $17.71. The trend has been persistently lower, with only brief and shallow rebounds punctuating the decline.

The longer view tells a similar story. Over the past quarter, the stock is down roughly 7%, easing from about $19.08 in late July. That pullback is part of a broader retreat from the mid-$20s seen in early July, indicating that selling pressure has been building for several months rather than appearing as a single, isolated event.

What Drove WATS Stock Price in the Last 30 Days

Several factors combined to pressure WATS in the recent period. Most notably, the company's latest reported quarter — the period ending in early July — showed a substantial GAAP net loss of $136 million, even as revenue stepped up sharply to $1.65 billion following the diagnostics acquisition. The loss, driven by acquisition-related charges and thinner margins, has kept profitability concerns front and center for investors.

Insider activity added to the cautious tone, with corporate insider sentiment described as negative and selling reported during the quarter, including a director's sale of shares in August. A leadership change in the analytical sciences division, announced in August, also introduced a degree of near-term uncertainty.

Analyst commentary has been mixed. While several firms maintained Buy ratings and raised price targets, others reiterated Hold ratings, leaving the stock without a clear consensus catalyst. Meanwhile, constructive developments — including cervical cancer screening partnerships with Labcorp (LH) and Quest Diagnostics (DGX) and the launch of AI-enabled LC-MS workflows — have not been enough to offset the selling pressure.

What Drove WATS Stock Performance Over the Last Quarter

The quarterly decline reflects a broader reassessment of Waters following its large-scale entry into diagnostics. Investors have focused on the execution risks of integrating Becton Dickinson's biosciences and diagnostics assets, including one-off losses, thinner margins, and the challenge of converting acquired scale into durable earnings. Softer demand in academic and pharmaceutical discovery end markets has compounded the pressure, while the stock's premium valuation left limited room for disappointment. These structural concerns have outweighed the positive momentum from recurring revenue growth and new product launches, keeping the shares in a multi-month downtrend.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of the platform's artificial intelligence-driven trading bots. While Tickeron offers hundreds of AI trading bots across thousands of tickers, only the top-performing and most relevant bots appear in this section. The featured bots vary in strategy, timeframe, and performance metrics, giving users a range of approaches to explore. For traders seeking systematic, data-driven signals alongside traditional analysis, this section offers a practical starting point to review how AI models are currently positioned across the market.

WATS Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, investors are likely to focus on Waters' upcoming quarterly earnings report and any updates to full-year guidance. Key areas to monitor include progress on integrating the diagnostics business, margin recovery, and whether the company can sustain recurring revenue growth. Adoption of newly launched AI-enabled workflows, demand trends in pharmaceutical and academic end markets, and the broader rotation in and out of life-science and technology names will also influence sentiment. Analyst price targets and ratings remain divided, so the stock's next directional move may depend on concrete evidence of improved profitability rather than headline announcements alone.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations